Opaque rebate retention collapses the moment regulators force transparent net-cost pricing.
To preempt antitrust action and state-level bans on vertical integration, pharmacy benefit managers are strategically abandoning spread pricing and offshore rebate pools in favor of flat-fee administrative models.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
It shows how PBMs are proactively shifting away from opaque rebate-retention models in response to mounting legislative and regulatory scrutiny.
Cigna is preempting legislative attacks on spread pricing and rebate retention by proactively migrating clients to transparent, fee-based structures.
This shift transitions the PBM's business model to transparent flat fees to bypass regulatory bans on spread pricing and rebate-retention.
CVS's PBM segment is experiencing margin compression as it transitions corporate accounts to transparent pricing to head off regulatory reform.
The health service arm of UnitedHealth is preemptively abandoning rebate retention for a flat-fee model to manage regulatory risk.